News Website

BioNTech’s Promising Phase III Trial: A Potential Game-Changer in Endometrial Cancer Treatment - TipRanks

BioNTech’s Promising Phase III Trial: A Potential Game-Changer in Endometrial Cancer Treatment TipRanks

Published: Oct. 27, 2025, 10:53 p.m.

Read Full Article

Iovance Biotherapeutics Advances in Endometrial Cancer Treatment with Lifileucel Study - TipRanks

Iovance Biotherapeutics Advances in Endometrial Cancer Treatment with Lifileucel Study TipRanks

Published: Oct. 27, 2025, 10:21 p.m.

Read Full Article

EDAP TMS S.A. Advances HIFU Treatment Study for Rectal Endometriosis - TipRanks

EDAP TMS S.A. Advances HIFU Treatment Study for Rectal Endometriosis TipRanks

Published: Oct. 27, 2025, 9:42 p.m.

Read Full Article

Aditxt Subsidiary Pearsanta Launches Clinical Study for Blood-Based Endometriosis Diagnostic - citybuzz -

Aditxt Subsidiary Pearsanta Launches Clinical Study for Blood-Based Endometriosis Diagnostic citybuzz -

Published: Oct. 27, 2025, 9:33 p.m.

Read Full Article

Acrivon Therapeutics Advances Phase 2 Study for Endometrial Cancer Treatment - TipRanks

Acrivon Therapeutics Advances Phase 2 Study for Endometrial Cancer Treatment TipRanks

Published: Oct. 27, 2025, 9:13 p.m.

Read Full Article

Monday's Health Report: What is endometriosis and how can it affect your life? - WBRZ

Monday's Health Report: What is endometriosis and how can it affect your life? WBRZ

Published: Oct. 27, 2025, 9:02 p.m.

Read Full Article

CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - The AI Journal

CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer The AI Journal

Published: Oct. 27, 2025, 7:50 p.m.

Read Full Article

CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - Yahoo Finance

CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer Yahoo Finance

Published: Oct. 27, 2025, 7:33 p.m.

Read Full Article

CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - Business Wire

CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer Business Wire

Published: Oct. 27, 2025, 7:33 p.m.

Read Full Article

Aspira Women’s Health Advances Endometriosis Diagnosis with EndoCheck Study - TipRanks

Aspira Women’s Health Advances Endometriosis Diagnosis with EndoCheck Study TipRanks

Published: Oct. 27, 2025, 6:47 p.m.

Read Full Article

Latest Articles

BioNTech’s Promising Phase III Trial: A Potential Game-Changer in Endometrial Cancer Treatment - TipRanks

Iovance Biotherapeutics Advances in Endometrial Cancer Treatment with Lifileucel Study - TipRanks

EDAP TMS S.A. Advances HIFU Treatment Study for Rectal Endometriosis - TipRanks

Aditxt Subsidiary Pearsanta Launches Clinical Study for Blood-Based Endometriosis Diagnostic - citybuzz -

Acrivon Therapeutics Advances Phase 2 Study for Endometrial Cancer Treatment - TipRanks

Monday's Health Report: What is endometriosis and how can it affect your life? - WBRZ

CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - The AI Journal

CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - Yahoo Finance

CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - Business Wire

Aspira Women’s Health Advances Endometriosis Diagnosis with EndoCheck Study - TipRanks

Subscribe to Our Newsletter